Company Profile
Enliven Therapeutics Stock Price, News & Catalysts
- Ticker:
- ELVN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
42.39 USD (-6.77%)
Close
Last updated: October 6, 2026
2.16B USD
Market cap
Why the stock is moving
The latest monitored company update is “Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia.” The corresponding closing-price reaction is not yet available.
Company overview
Precision Oncology
Enliven Therapeutics develops small-molecule precision medicines intended to improve both survival and quality of life for people with cancer.
ELVN-001
ELVN-001 is a selective BCR::ABL1 tyrosine-kinase inhibitor for chronic myeloid leukemia. It is designed to retain antileukemic activity while reducing off-target effects associated with existing therapies.
Late-Stage Development Path
Clinical development is moving from Phase 1 evaluation toward the pivotal ENABLE-2 program, positioning ELVN-001 as the company's principal potential registrational asset.
Future catalysts
- Phase 1 data update for ELVN-001 around mid-2026.
- Initiation of the Phase 3 ENABLE-2 trial in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Enliven Therapeutics (ELVN)?
Enliven Therapeutics (ELVN) most recently closed at 42.39 USD, a -6.77% move versus the previous session.
What is the market cap of Enliven Therapeutics (ELVN)?
Enliven Therapeutics currently has a market capitalization of 2.16B USD on BioPharmSignal.
What does Enliven Therapeutics do?
Precision Oncology Enliven Therapeutics develops small-molecule precision medicines intended to improve both survival and quality of life for people with cancer. ELVN-001 ELVN-001 is a selective BCR::ABL1 tyrosine-kinase inhibitor for chronic myeloid leukemia. It is designed to retain antileukemic activity while reducing off-target effects associated with...
On which exchange is ELVN stock listed?
Enliven Therapeutics (ELVN) is associated with NASDAQ, United States, Biopharma.
What is ELVN-001?
Phase 1 data update for ELVN-001 around mid-2026.
Which conditions is Enliven Therapeutics targeting with ELVN-001?
Enliven Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Enliven Therapeutics describe recent progress with ELVN-001?
Phase 1 data update for ELVN-001 around mid-2026.
What is ENABLE-2?
Late-Stage Development Path Clinical development is moving from Phase 1 evaluation toward the pivotal ENABLE-2 program, positioning ELVN-001 as the company's principal potential registrational asset.